Vericiguat is a
soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and
heart failure (HF) hospitalization in adults with symptomatic chronic HF and ejection fraction less than 45%. Guidelines recommend short-acting
nitrates, such as sublingual
nitroglycerin, for the treatment of acute
angina pectoris in patients with chronic coronary syndromes (CCSs), common comorbidities in HF. We evaluated safety, tolerability, and the pharmacodynamic interaction between
vericiguat and
nitroglycerin, coadministered in patients with CCSs. In this phase Ib, double-blind, randomized, multicenter study, 36 patients with CCSs received either
vericiguat 2.5 mg (up-titrated every 2 weeks to 5 mg and 10 mg) or placebo. Patients also received
nitroglycerin (0.4 mg sublingual). In total, 31 patients completed the study (
vericiguat +
nitroglycerin, n = 21; placebo +
nitroglycerin, n = 10). There was no increase in treatment-emergent adverse events (TEAEs) with
vericiguat +
nitroglycerin vs. placebo +
nitroglycerin; three patients discontinued due to TEAEs (
vericiguat +
nitroglycerin, n = 1; placebo +
nitroglycerin, n = 2). Decreases in mean blood pressure (BP; 6-10 mmHg systolic BP (SBP); 4-6 mmHg diastolic BP (DBP)) were independent of
vericiguat exposure and occurred to a similar extent at trough and peak concentrations with all
vericiguat doses and placebo. Coadministration of
vericiguat with
nitroglycerin in patients with CCSs was well tolerated, and the combination is unlikely to cause significant adverse effects beyond those known for
nitroglycerin.